AI Article Synopsis
- The study aimed to investigate the effects of fluoxetine on mandibular bone formation in rats during pregnancy and lactation.
- It involved 24 Wistar rat pups divided into four groups, with some receiving fluoxetine during gestation and/or lactation, and various analyses were conducted on their mandibles at 25 days old.
- Results indicated that fluoxetine treatment led to reductions in mandibular bone mass, including decreased thickness, fewer osteocytes, and lower bone density, particularly in those treated during both gestation and lactation.
Article Abstract
Aim: To verify whether the use of fluoxetine during gestation and lactation interferes in mandibular bone formation in rats.
Methods: Twenty-four Wistar rat pups were used and distributed into four groups: CG - control of gestation; CL - control of gestation and lactation; FG - treated with fluoxetine during gestation and FL - treated with fluoxetine during gestation and lactation. At 25 days of life, after anesthesia, perfusion and decapitation, the mandibles were removed. Radiographic, histologic, histometric and polarizing microscopy analyses were performed. Statistical analysis was used considering a level of 5% significance.
Result: The FL group compared with its control (CL) was shown to differ statistically from the other groups as regards histometry and radiopacity, revealing a reduction in the inferior cortical thickness, reduction in number of osteocytes, with consequent reduction in radiographic bone density. There was also reduction in the number of osteoblasts in FG.
Conclusion: The long-term use of fluoxetine via oral route by pregnant and lactating rats modifies the mandibular bone mass.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.acthis.2015.05.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of congenital anomalies associated with psychotropic medications: a review of neonatal reports in the FDA adverse event reporting System (FAERS).
Arch Womens Ment Health
December 2024
College of Pharmacy, Jinan University, Guangzhou, Guangdong, China.
Purpose: This study investigates the potential association between commonly prescribed psychotropic medications, such as Atypical Antipsychotics (AAs), Selective Serotonin Reuptake Inhibitors (SSRIs), and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), and congenital anomalies in newborns. The analysis uses data from the Food and Drug Administration Adverse Event Reporting System (FAERS).
Methods: Spontaneously reported cases of congenital anomalies in newborns (under 28 days old) were extracted from the FAERS database, covering January 2004 to June 2023.
Association between psychopharmacotherapy and postpartum hemorrhage.
AJOG Glob Rep
November 2024
Northwell, New Hyde Park, NY (Jackson, Kouba, Meirowitz, Keller, Bracero, and Blitz).
Background: Prior studies evaluating the relationship between psychopharmacotherapy (PPT), and postpartum hemorrhage (PPH) have yielded inconsistent findings. Clarifying this potential relationship is important for effective counseling and risk stratification.
Objectives: Our primary objective was to evaluate the association between prenatal exposure to PPT (any drug class) and the occurrence of PPH requiring transfusion of packed red blood cells (PPH+pRBC) after systematically adjusting for known hemorrhage risk factors at the time of admission for delivery.
Assessing the Neurodevelopmental Impact of Fluoxetine, Citalopram, and Paroxetine on Neural Stem Cell-Derived Neurons.
Pharmaceuticals (Basel)
October 2024
Department of Pharmaceutical Bioscience, Uppsala University, 751 24 Uppsala, Sweden.
Background/objectives: Many pregnant women globally suffer from depression and are routinely prescribed selective serotonin reuptake inhibitors (SSRIs). These drugs function by blocking the re-uptake of serotonin by the serotonin transporter (SERT) into neurons, resulting in its accumulation in the presynaptic cleft. Despite a large amount of research suggesting a potential link to neurodevelopmental disorders in children whose mothers took these drugs during pregnancy, their possible adverse effects are still debated, and results are contradictory.
View Article and Find Full Text PDFExploring genetic causal relationship between antidepressants use and congenital malformations.
Reprod Toxicol
December 2024
Changzhou Maternal and Child Health Care Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, China; International Genome Center, Jiangsu University, Zhenjiang, China. Electronic address:
Article Synopsis
- * The findings suggest a possible link between antidepressant use and specific congenital malformations, particularly digestive and respiratory system issues related to SSRIs, but no significant associations were found for citalopram, paroxetine, or sertraline.
- * The authors conclude that while there is some evidence of a causal relationship between certain antidepressants and congenital malformations, more research is necessary to verify these results and understand the biological mechanisms involved.
Autism spectrum disorder-like behaviors induced by hyper-glutamatergic NMDA receptor signaling through hypo-serotonergic 5-HT receptor signaling in the prefrontal cortex in mice exposed to prenatal valproic acid.
Neuropsychopharmacology
October 2024
Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Aichi, Japan.
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by repetitive behaviors, social deficits, and cognitive impairments. Maternal use of valproic acid (VPA) during pregnancy is associated with an increased risk of ASD in offspring. The prevailing pathophysiological hypothesis for ASD involves excitation/inhibition (E/I) imbalances and serotonergic dysfunction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!